GMAB Earnings

GMAB reported its earnings on 2026-02-17, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.46 by 0%. The stock experienced a -0.1% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following GMAB's earnings announcement on 2026-02-17, the stock price moved by -0.1% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, GMAB's stock price tends to shift by an average of 3.42% in the 10 days leading up to earnings and 3.58% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate GMAB's annual revenue to reach 961.58M, while the EPS is projected at 0.45. These estimates reflect recent revisions, with revenue estimates revised upward by 1.58% and EPS estimates revised upward by 1.23% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GMAB's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 1.58%, while EPS estimates moved revised upward by 1.23%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GMAB's stock price typically moves by 3.42% in the 10 days before its earnings and 3.58% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.45 and revenue of 961.58M.

The earnings call highlights strong future revenue projections, significant product pipeline developments, and strategic market expansions, which are positive indicators. The Q&A section reveals management's optimism about trial outcomes and market strategies, despite some vagueness in responses. The company's focus on strategic acquisitions and disciplined financial management further supports a positive outlook. However, the lack of interim trial details could cause some uncertainty. Overall, the strong revenue and product potential, combined with strategic growth plans, suggest a positive stock price movement in the short term.